• Medidata published its 2026 “State of AI in Clinical Trials” report, pointing to a shift from pilot projects toward enterprise adoption across life sciences clinical development.
• Among “early adopters” with more than 18 months of AI experience, 72.9% reported shorter clinical trial timelines; 67.5% reported fewer protocol deviations.
• Investment intentions remained strong, with 92% of respondents planning to increase AI spending; 82% expected a 2-3x ROI, with 63% targeting payback within 12-24 months.
• Execution risks persisted, led by integration complexity cited by 79.5% of respondents, model accuracy at 77.5%, weak data foundations at 75%.
• Governance requirements were a gating factor, with more than 63% rating data trust and regulatory compliance as critical; 64.5% required legal and compliance review; 63% mandated human oversight.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medidata Solutions Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.